Evidence map›Paper›PMID 41499232›Full record

ArticleCancer medicine2026

Molecular Deconvolution of Circulating "Other Cells": A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients Receiving

Mahesh K Padwal, Rahul V Parghane, Sandip Basu, Bhakti Basu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mahesh K PadwalMolecular Biology Division, Bhabha Atomic Research Centre, Mumbai, India.ORCID https://orcid.org/0000-0003-4715-1108
Rahul V ParghaneHomi Bhabha National Institute, Mumbai, India.
Sandip BasuHomi Bhabha National Institute, Mumbai, India.
Bhakti BasuMolecular Biology Division, Bhabha Atomic Research Centre, Mumbai, India.ORCID https://orcid.org/0000-0002-7381-6671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the prognostic impact of pre-treatment circulating other cells on treatment response and survival in neuroendocrine tumor (NET) patients receiving Peptide Receptor Radionuclide Therapy (PRRT) with

methodsHealthy donors (HDs, n = 81) and NET patients (n = 137) were analyzed. Baseline circulating other cells proportions (OC%) were deconvoluted from RNA-Seq profiles using the Kassandra-B algorithm. Associations of OC% with demographic and clinicopathologic characteristics, tumor response to PRRT, and survival outcomes were evaluated.

resultsNET patients had a significantly higher OC% compared to HDs (median = 0.26 vs. 0.18, p = 0.0018). A positive correlation was observed between OC% and the tumor grade (G3 tumors: median = 0.47, G1 tumors: median = 0.22, p = 0.029) or disease burden (high: median = 0.32, low: median = 0.23, p = 0.016). The OC% was negatively associated with

conclusionsPre-treatment OC%, in conjunction with critical risk factors, is predictive of treatment response and survival in NET patients receiving

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsRadiopharmaceuticalsAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisReceptors, PeptideTreatment OutcomeBiomarkers, Tumorlutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, Peptide177Lu‐DOTATATE PRRTdisease control rateneuroendocrine tumorsother cell proportionsprognosis

Identifiers

PMID41499232
PMCPMC12778296

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.